METHODS: In a prospective, open-label, multicenter pharmacokinetic study, intensive care unit (ICU) patients prescribed azoles, echinocandins, or polyene antifungals for treatment or prophylaxis of invasive fungal disease were enrolled. Blood samples were collected on two occasions, with three samples taken during a single dosing interval on each occasion. Total concentrations were centrally measured using validated chromatographic methods. Pharmacokinetic parameters were estimated using noncompartmental methods. Antifungal dosing adequacy was assessed using predefined PK/PD targets.
RESULTS: We included 339 patients from 30 ICUs across 12 countries. Median age 62 (interquartile range [IQR], 51-70) years, median APACHE II score 22 (IQR, 17-28), and 61% males. Antifungal therapy was primarily prescribed for treatment (80.8%). Fluconazole was the most frequently prescribed antifungal (40.7%). The most common indication for treatment was intra-abdominal infection (30.7%). Fungi were identified in 45% of patients, of which only 26% had a minimum inhibitory concentration available. Target attainment was higher for patients receiving prophylaxis (> 80% for most drugs). For patients receiving treatment, low target attainment was noted for voriconazole (57.1%), posaconazole (63.2%), micafungin (64.1%) and amphotericin B (41.7%).
CONCLUSION: This study highlights the varying degrees of target attainment across antifungal agents in critically ill patients. While a significant proportion of patients achieved the predefined PK/PD targets, wide variability and subtherapeutic exposures persist.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03136926, 2017-04-21.
AIMS: This study aims to contribute to the existing knowledge by investigating the association and time lags (TLs) between daily microclimate (DM), mosquito indices (MIs), and dengue cases at the residence level.
METHODS: In this longitudinal study, field data were collected over 26 weeks using data loggers, gravid oviposit sticky (GOS) traps, and non-structural 1 (NS1) test kits in both non-dengue hotspot (NDH) and dengue hotspots (DH). The collected data encompassed DM variables, vegetation cover (VC), MIs, and number of dengue cases. An autocorrelation analysis was conducted to determine the TLs between MIs and their preceding values, while a cross-correlation analysis revealed the TLs between MIs and DM variables.
RESULTS: The study indicated there are positive correlations between the adult index (AI) of Ae. albopictus, their preceding values and rainfall at an NDH. Conversely, the AIs of total Aedes at the DH exhibited positive correlations with their preceding values, temperature, rainfall, and maximum relative humidity (RH), but negative correlations with the mean and maximum RH. The dengue-positive trap index (DPTI) of total Aedes at DHs demonstrated positive associations with their preceding values, mean temperature, minimum temperature, maximum RH, and rainfall, with negative correlations observed for the maximum temperature, mean RH, and minimum RH. Similar trends were identified for the Ae. aegypti and Ae. albopictus at DHs. The association between dengue cases, DM, and MIs was inconclusive due to underreported cases.
CONCLUSIONS: This study highlighted the DM and TLs of dengue virus-infected and non-infected adult female Aedes mosquitoes using onsite data collection. Furthermore, this study presents a replicable methodology that can be adopted by researchers worldwide for investigating the dynamics of dengue transmission in similar settings. The findings offer valuable insights for decision-makers, providing them with evidence-based information to implement targeted interventions and strategies aimed at controlling Aedes mosquito populations and mitigating the spread of dengue virus infections.
METHOD: An open-labeled, randomized control trial performed from April 2023 to July 2023 in the nephrology unit of a tertiary care setting in Peshawar Pakistan. Those patients who met the inclusion criteria were randomized into two groups 1:1, i.e., control and intervention group. Clinical pharmacists identified the DRPs at baseline using Pharmaceutical Care Network Europe (PCNE) 9.1 guidelines. The QoL of patients were assessed at baseline and endpoint by using the Functional Assessment of Non-Life-Threatening Conditions (FANLTC) questionnaire.
RESULTS: A total of 100 patients were recruited having 50 in each group. The pharmacist identified a total of n = 230 DRPs in the intervention group, majority of the DRPs were attributed to inappropriate drug selection according to guidelines/formulary"; "inappropriate combinations of drugs or with herbal medications or dietary supplements"; and situations where "too many different drugs or active ingredients were prescribed". There was 46.52% reduction in the DRPs while comparing baseline and endpoint interventions suggested by pharmacist in the intervention group. The clinical pharmacist provided interventions in order to resolve the DRPs, and 37.40% interventions were accepted and fully implemented; 31.30% of the interventions were accepted and partially implemented. The clinical pharmacist identification and proposed intervention for DRPs contributed to a statistically significant improvement in QoL, from mean ± SD scored 58.64 ± 9.10 at the baseline to 74.48 ± 10.11 at the endpoint, with a p-value of
OBJECTIVE: To identify studies of behavioural activation designed for people with cancer and examine the effects on psychological distress, including depression and anxiety.
DESIGN: Systematic review and meta-analysis.
METHODS: A systematic search of PubMed/MEDLINE, CINAHL, EMBASE, PsycINFO, and the Cochrane Library was performed from the inception to 6 April 2024. Randomised controlled trials reporting on the effects of behavioural activation on psychological distress among cancer patients were included. Two authors independently screened the eligible studies, assessed the quality of studies, and extracted data. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2). The meta-analysis was performed by Review Manager 5.4, and narrative synthesis was employed when the meta-analysis was inappropriate. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was used to assess the certainty of the evidence.
RESULTS: A total of nine studies were included in this systematic review, with 1811 participants. The pooled analysis showed that behavioural activation could improve depression (SMD = -0.24, 95 % CI -0.44 - -0.03, p = 0.020; moderate quality of evidence), and anxiety (SMD = -0.56, 95 % CI -1.01 - -0.10, p = 0.020; low quality of evidence) among people with cancer. The effects were robust in sensitivity analysis and yielded consistent results in studies that were not pooled due to insufficient data. Subgroup analyses suggested that face-to-face and group administration were more effective, whereas the effects of different dosages were uncertain. Besides, the effects of behavioural activation at different follow-up periods were not identified There was no consensus on the optimal components of intervention.
CONCLUSIONS: The evidence for behavioural activation as an effective treatment of psychological distress among people with cancer is promising. However, it should be noted that the quality of evidence was moderate and low, thus emphasising the need for caution when applying these findings. In order to explore which components may be most effective in improving psychological outcomes, more rigorous study designs and more detailed descriptions of interventions are necessary.
REGISTRATION: The protocol was registered on PROSPERO (Registration number: CRD42024533171).
METHODS: A microsimulation decision tree model was used to model the ACT NOW intervention (including annual clinical breast examination (CBE) and biannual breast ultrasound for women at high risk of breast cancer) over 5 years for healthy women 40-69 years old. Outcomes included health gains (breast cancer deaths saved), financial protection (financial catastrophes saved) and incremental cost-effectiveness ratios (ICER) (cost per disability-adjusted life year (DALY) saved). Outcomes were stratified by income group. Probabilistic, one-way sensitivity and scenario analyses explored uncertainty.
RESULTS: Over 5 years, the ACT NOW intervention is cost-effective with an ICER of PHP60 711 (USD1098) (average incremental cost PHP743 [95% UI 424-960] and DALYs saved 0.01 [95% UI 0.01-0.02], below Philippines 2022 gross domestic product per capita PHP178 751). Per 100 000 women, 57 deaths and eight financial catastrophes were saved. Cost-effectiveness did not vary significantly by income, but higher income groups incurred greater costs and lower DALYs. Results were sensitive to proportion of late-stage breast cancers post intervention, treatment adherence, intervention costs and downstaging effectiveness. Trade-offs are apparent between government contributions to financial protection and rates of financial catastrophe.
CONCLUSIONS: Early detection interventions (annual CBE, biannual breast ultrasound if at high risk of breast cancer) are likely to be cost-effective, reduce breast cancer-related mortality through detection at earlier stages and modestly effective in reducing the incidence of financial catastrophe. Further research is required to establish the best implementation model to pursue full implementation and ways of designing equity-based screening interventions.
METHODS: A survey conducted among APASL members from 2 Aug to 30 Oct, 2023, gathered data on antiviral HBV drugs, treatment costs covering stages of chronic hepatitis B (CHB), compensated cirrhosis (CC), hepatocellular carcinoma (HCC), liver transplant, and monitoring expenses. Drug costs for TDF and ETV were compared to international reference price (TDF: $30, ETV: $36 per person per year), generating a median price ratio (MPR) where MPR
METHODS: The surveys were simultaneously done in Eastern and Sarawak administrative regions using the Rapid Assessment of Avoidable Blindness (RAAB) technique. It involved a multistage cluster sampling method, each cluster comprising 50 residents aged 50 years and older. Presenting visual acuity (PVA) was checked, and subjects with cataracts were identified. The corrected VA (Pinhole) of those who had undergone cataract surgery was measured. eCSC was calculated at all levels of cataract surgical thresholds according to the protocol. The findings were compared with the previous survey.
RESULTS: A total of 10,184 subjects were enumerated, with 9,709 examined and 475 non-respondents. Females had a significantly lower Cataract Surgical Coverage (CSC) than males for cataract surgical threshold of
METHODS: Seventy-one medication-naïve patients and 71 healthy controls (HCs) aged 18 to 28 underwent clinical interviews, Conners' Adult ADHD Rating Scale (CAARS) questionnaire, functional near-infrared spectroscopy (fNIRS), oculomotricity task, and Conners' Continuous Performance Task (CPT) 3rd edition. Student's t-tests with Bonferroni's correction were performed to compare the performance between groups, and logistic regression was used for classification.
RESULTS: ADHD patients had significantly lower frontal hemodynamic response during verbal fluency task (VFT) (P = 0.0003), more anticipatory eye movements during overlap task (P = 0.0006), higher latency (P